Wendy Cai

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

Richard Furie, William Stohl, Ellen M. Ginzler et al. · Arthritis Research & Therapy · 2008 · 264 citations · Full text

Life Sciences, Immunology, Pharmacology +13

Chronic Administration of Belimumab, a BLyS Antagonist, Decreases Tissue and Peripheral Blood B-Lymphocyte Populations in Cynomolgus Monkeys: Pharmacokinetic, Pharmacodynamic, and Toxicologic Effects

Wendy Halpern, Patrick B. Lappin, Thomas A. Zanardi et al. · Toxicological Sciences · 2006 · 156 citations

Life Sciences, Immunology, Pharmacology +17

Safety, Pharmacokinetics, and Antiviral Activity of HGS004, a Novel Fully Human IgG4 Monoclonal Antibody against CCR5, in HIV‐1–Infected Patients

Jacob Lalezari, Gopal Yadavalli, Michael F. Para et al. · The Journal of Infectious Diseases · 2008 · 72 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +11

Developmental and peri-postnatal study in cynomolgus monkeys with belimumab, a monoclonal antibody directed against B-lymphocyte stimulator

Diana J. Auyeung-Kim, Madhav N. Devalaraja, Thi‐Sau Migone et al. · Reproductive Toxicology · 2009 · 59 citations

Life Sciences, Immunology, Pharmacology +16

Population Pharmacokinetics of Belimumab Following Intravenous Administration in Patients With Systemic Lupus Erythematosus

Herbert Struemper, Cecil Chen, Wendy Cai · The Journal of Clinical Pharmacology · 2013 · 54 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +9